In Brief: Dr. Kremer's PMA
This article was originally published in The Gray Sheet
Dr. Kremer's PMA: FDA Ophthalmic Devices Panel recommends against approval of a single-site premarket approval application sponsored by Frederic Kremer, MD, for a system to perform laser- assisted in situ keratomileusis. In a 4-2 vote, panel members cite poor patient accountability and inadequate standardization of post-operative patient evaluation. Kremer's PMA for the Laser-K laser-based system included data on 2,500 patients in two study cohorts. Uncorrected visual acuity at one-year follow-up was 92.2% for one group, 87.4% for the other cohort. The panel's rejection of the PMA likely will deal a blow to a licensing agreement between Kremer and Lasersight. Under the deal, Kremer must obtain a PMA approval allowing Lasersight to commercialize a LASIK system by July 28, or else the company can return the technology to Kremer...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.